Sarfaraz Niazi, PhD, urges the FDA to let the USPharmacopeia (USP) create product release specifications for biosimilars to cut costs, speed development, and enhance accessibility. My citizen ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...

Remsima is a biosimilar to Johnson & Johnson’s autoimmune disease treatment, Remicade. It is the world’s first antibody biosimilar, inspiring global pharmaceutical companies to pursue the ...

Andy Harries, the founder and CEO of Sony-owned Left Bank Pictures and an exec producer on its hit show “The Crown,” is to transition to an executive chairman role after 18 years at the helm ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Does Donald Trump want Canadian oil or does he want to block us? It really depends when you ask him it seems, or what mood he is in.

Results from the phase 3 trial showed biosimilar denosumab was comparable to the reference product with regard to efficacy, safety, immunogenicity, PK, and pharmacodynamics (PD) in patients with ...

John­son & John­son is su­ing Sam­sung Bioepis for al­leged­ly breach­ing the terms of a con­tract re­gard­ing the launch of the Ko­re­an biotech’s Ste­lara biosim­i­lar. … ...

The launch marks a significant move, as YESINTEK is among the first biosimilar alternatives to Stelara (ustekinumab) to enter the US market. YESINTEK is approved for Crohn’s disease, ulcerative ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar. Johnson & Johnson on Monday sued Samsung ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...